We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Nanoparticle Assay Detects Respiratory Bacteria in Pneumonia Model

By LabMedica International staff writers
Posted on 13 Dec 2018
Researchers used a mouse pneumonia model to demonstrate how a nanoparticle-based technique could be used to detect Pseudomonas aeruginosa bacteria in infected animals and monitor bacterial clearance from their lungs during the course of antibiotic treatment.

Respiratory tract infections represent a significant public health risk, and timely and accurate detection of bacterial infections facilitates rapid therapeutic intervention. More...
Furthermore, monitoring the progression of infections after intervention enables alternative therapy in cases where initial treatments were ineffective, avoiding unnecessary drug dosing that could contribute to antibiotic resistance. However, current diagnostic and monitoring techniques rely on non-specific or slow methods, such as radiographic imaging and sputum cultures, which fail to specifically identify bacterial infections and take several days to identify optimal antibiotic treatments.

To improve the diagnostic situation, investigators at the Massachusetts Institute of Technology (Cambridge, USA) modified a "nanoparticle sensor" assay that they had developed previously to detect tumors. This technique utilized nanoparticles coated with peptides that could be digested by certain proteases (such as those expressed by cancer cells). Following injection, the particles accumulated in tumors, where the proteases cleaved the peptides from the surface of the nanoparticles. The peptides were eliminated as waste and were detected by a simple urine test.

In the current study, one protease sensor comprised a peptide substrate for the P. aeruginosa protease LasA. A second sensor was based on elastase protein and detected the recombinant enzyme neutrophil elastase as well as secreted proteases from bacterial strains.

The investigators reported in the November 29, 2018, online edition of the journal EBioMedicine that nanoparticle formulations of these protease sensors (termed activity-based nanosensors or ABNs) detected P. aeruginosa in infected mice and monitored bacterial clearance from the lungs over time. Additionally, ABNs differentiated between appropriate and ineffective antibiotic treatments acutely, within hours after the initiation of therapy.

“If the patient’s symptoms go away, then you assume the drug is working. But if the patient’s symptoms do not go away, then you would want to see if the bacteria are still growing. We were trying to address that issue,” said senior author Dr. Sangeeta Bhatia, professor of health sciences and technology, electrical engineering, and computer science at the Massachusetts Institute of Technology. “We have been working on this idea that measuring enzyme activity could be a new way to peer inside the body. The sensors can help you distinguish between whether there is an infection and inflammation, versus inflammation and no infection. What we showed in the paper is that when you treat with the right antibiotic, the infection goes down but the inflammation persists.”

Related Links:
Massachusetts Institute of Technology


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Luteinizing Hormone Test
Luteinizing Hormone (LH) Rapid Test
New
Giardia Assay
AccuDiag Giardia
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Gut microbes may help in recognizing and treating pancreatic cancer (Photo courtesy of Adobe Stock)

Gut Microbes Could Enable Early Detection and Treatment of Pancreatic Cancer

Pancreatic cancer remains one of the most serious and challenging diseases in oncology due to its difficulty in detection and limited treatment options. Now, a new international collaborative study suggests... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The U.S. FDA-cleared IntelliSep rapid host response diagnostic represents a breakthrough in sepsis care (Photo courtesy of Cytovale)

Rapid Diagnostic Test Slashes Sepsis Mortality by 39%

Sepsis remains one of the most challenging and fatal conditions in contemporary healthcare, accounting for nearly one-third of all hospital-related deaths in the United States. In emergency departments... Read more

Industry

view channel
Image: The knowledge transfer partnership will further develop technology to rapidly diagnose serious and high-risk infectious diseases (Photo courtesy of Aston University)

Aston University and BG Research Partner to Commercialize Groundbreaking Medical Diagnostic

Technology that can rapidly diagnose high-consequence infectious diseases will take a major step forward towards commercialization, thanks to a new partnership. A Knowledge Transfer Partnership (KTP)... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.